
Intensity Therapeutics, Inc. to Present at the Biotech Showcase Conference in San Francisco

- Presentation to be January 12 at 2:15PM in Parc 55 Wyndham Hotel

January 6, 2015 (Westport, CT) - Intensity Therapeutics, Inc. (private), developing novel cancer immunotherapy products, announced that President and CEO Lewis H. Bender will present at the 7th Annual Biotech Showcase & Investor Conference on Monday, January 12, 2015 at the Parc 55 Wyndham Hotel, 55 Cyril Magnin Street in San Francisco at 2:15PM (PST) in the Hearst Room (located on the 4th Floor). Mr. Bender will provide an overview of the Company's technology and an update on product development activities. Mr. Bender and Ian B. Walters, MD (Chief Medical Officer) will be available for one-on-one meetings with investors during the week.

About Intensity Therapeutics, Inc.

Intensity Therapeutics, Inc. is a biotechnology company whose mission is to greatly extend the lives of patients with cancer. Intensity Therapeutics is pioneering a new immunotherapy approach to treat cancer referred to as [in situ chemovaccination](#). The Company's novel products when injected directly into tumors result in tumor regression from baseline and significantly increased survival. The technology attenuates (kills) a tumor in a manner that allows for the adaptive immune system to recognize the cancer to attack untreated tumors and prevent disease recurrence. Further information can be found at www.intensitytherapeutics.com

Contact:

Media & Investors:

Lewis Bender

President & CEO

8 Wright Street, Suite 107

Westport, CT 06880

Tel. (203) 682-2434

Email: lbender@intensitytherapeutics.com

Forward-Looking Statements

This press release contains forward-looking statements regarding Intensity Therapeutics' plans, future operations and objectives. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual performance or achievements to be materially different from those currently anticipated. These forward-looking statements include, among other things, statements about the initiation and timing of future clinical trials.